Tefron Follow-Up: Working Capital, Covenant Headroom, And The 2026 Funding Test
The main article argued that Tefron’s balance sheet funded its transition year. This follow-up shows the bridge itself: customer terms lengthened, inventory days rose, supplier funding weakened, and the gap moved to the bank. That is why a 1.32 debt-service coverage ratio matters more right now than a 0.96 debt-to-EBITDA ratio.
The main article already made the big point: retail bought Tefron time, and the balance sheet funded the transition year. This follow-up isolates the technical layer that will shape how 2026 is read: how working capital was actually built, who funded it, and why the covenant that matters is debt-service coverage rather than debt to EBITDA.
The good news is that this is not a classic leverage crisis. The less comfortable part is that the apparent improvement in receivables did not come from cleaner terms, inventory did not unwind, supplier funding shrank, and the bank took a larger role in the funding stack. That is why the 2026 test is not whether Tefron has “too much debt” in the abstract. It is whether the company can rebuild breathing room between EBITDA and debt service without another round of financing adjustments.
Four points matter immediately:
- First finding: the excess of current assets over current liabilities fell to $37.9 million from $46.1 million, yet rose slightly as a share of sales to 16.0% from 15.7%.
- Second finding: receivables fell by $15.2 million, but customer credit days increased in both operating segments.
- Third finding: inventory did not clear. It rose to $49.7 million from $48.5 million, while company-wide inventory days increased to 93 from 79.
- Fourth finding: supplier payables fell by $12.2 million, while gross bank debt jumped to $23.0 million from $5.0 million.
Working Capital Only Looks Stable From The Top
The headline line, working capital at 16% of sales, sounds almost calm. That is only half true. At the top level the ratio does not look dramatic. Inside the bridge, the mix changed sharply: receivables came down, but not because collection quality improved; suppliers came down as well, meaning less trade funding stayed in the system; and inventory remained heavy. The bank filled the gap between those moving pieces.
| Item | 2024 | 2025 | Change | What it means |
|---|---|---|---|---|
| Excess current assets over current liabilities | $46.1 million | $37.9 million | $8.1 million down | Absolute working capital weakened |
| Net receivables | $49.6 million | $34.3 million | $15.2 million down | The balance fell, but not because terms improved |
| Inventory | $48.5 million | $49.7 million | $1.2 million up | Inventory did not unwind |
| Supplier payables | $44.7 million | $32.5 million | $12.2 million down | Trade funding weakened |
| Gross bank debt | $5.0 million | $23.0 million | $18.0 million up | Funding shifted to the bank |
The receivables decline is especially easy to misread. In brands, receivables fell to $13.4 million from $27.1 million, but average customer credit days increased to 115 from 98 because one customer received extended terms. In retail, receivables slipped only to $21.0 million from $22.4 million while average customer credit days rose to 51 from 43. The company links that increase to sales mix and to lower activity with a customer that uses an accelerated-payment program. In other words, the receivables balance looks better mainly because revenue fell, not because cash conversion structurally improved.
That point matters because Tefron does use payment-acceleration tools. With Wal-Mart and Target, actual payment terms are shortened to up to 30 days in exchange for an interest charge. The company also uses accelerated-payment programs for major customers through Wells Fargo at 1% + SOFR. That is a legitimate tool, but it means the receivables balance does not tell the whole liquidity story on its own. When activity with one of those customers falls, customer days can worsen even if the balance itself does not spike.
Inventory tells the other half of the story. The company says it typically does not hold raw materials for extended periods, but during 2025 frequent changes in U.S. tariff policy caused some customers to shorten delivery timelines. To meet those timelines, Tefron began receiving commitments from customers to cover yarn procurement costs for advance stocking. Even with that support, inventory did not release. Work in process rose to $4.6 million from $2.9 million, total inventory increased to $49.7 million, and the company recorded a $2.289 million slow-moving inventory write-down versus $965 thousand the year before.
Days moved the wrong way as well. Company-wide inventory days rose to 93 from 79. In brands they increased to 99 from 77, and in retail to 92 from 80. That means 2026 does not start from a cleaner balance sheet. It starts from heavier inventory and a slower inventory cycle.
Who Actually Funded 2025
The right framing here is all-in cash flexibility. This is not a normalized earnings-power view. It is a test of how much cash remained after the year’s actual cash uses. That is the right frame in Tefron’s case because the issue is financing flexibility, not theoretical cash generation.
On that basis, 2025 did not fund itself. Cash flow from operations came in at $11.0 million. Against that stood $19.9 million of net cash investment, $2.9 million of lease principal repayment, $2.1 million of dividends, $1.5 million of royalty-liability repayment, $960 thousand paid against the liability for the acquired activity, and roughly another $1.0 million of loan and equipment-credit repayments. Before new bank borrowing, the cumulative gap was about $17.2 million. That wording matters: this bridge includes lease principal repayment, not total lease-related cash outflow.
The bank closed that gap. Net short-term bank borrowing increased by $8.5 million, and the company also received a new $10.0 million term loan. By year-end, gross bank debt stood at $23.0 million, cash at $7.7 million, and net financial debt at roughly $15.3 million.
This did not happen because suppliers carried more of the load. The opposite is true. Total supplier credit fell to $32.5 million from $44.9 million. In retail alone, supplier balances fell to $24.4 million from $36.3 million while supplier days moved only slightly, to 84 from 87. That means the decline in trade funding was much more about fewer dollars of supplier support than about a major change in terms. In practical terms, Tefron ended 2025 with less supplier funding and more bank funding.
The unused line should also be read carefully. At year-end the company had about $33 million of unused availability, but that availability is derived from the current collateral base. It is not a separate pool of free cash. It depends on receivable quality, inventory eligibility, and what the bank is willing to recognize under the agreement.
Why Debt-Service Coverage Is The Real Covenant
At first glance, debt to EBITDA looks comfortable enough to calm investors. The ratio stood at 0.96 against a ceiling of 3.50, and the presentation also shows net financial debt of $15.3 million against last-twelve-month EBITDA of $18.1 million. That is not an obvious balance-sheet stress signal.
But that is not the covenant that tells the 2026 story. The more relevant test is debt-service coverage. At year-end it stood at 1.32 against a minimum threshold of 1.20. That is only 0.12 of headroom above the floor. In covenant terms, it is materially tighter than the 2.54 turns of room the company still has under debt to EBITDA.
| Covenant | Requirement | Actual | Headroom | How to read it |
|---|---|---|---|---|
| Debt-service coverage ratio | At least 1.20 | 1.32 | 0.12 above the floor | This is the cash-flow-to-bank test, so it is the tighter friction point |
| Debt to EBITDA | No more than 3.50 | 0.96 | 2.54 below the ceiling | This is still a very loose balance-sheet test |
Why is debt-service coverage the tighter constraint? Because it meets the exact place where 2025 weakened: last-twelve-month EBITDA fell to $18.1 million from $34.2 million, while the company added a more meaningful layer of bank debt. Debt to EBITDA also benefits from netting out cash, which is why it still looks relaxed. Debt-service coverage tests the distance between EBITDA and what the bank actually needs to be paid.
The clearest clue comes from the June 2025 amendment to the financing agreement. The main relief did not come through covenant easing. It came through what the bank would recognize inside borrowing availability: the cap on in-transit inventory eligible for the borrowing base increased from $3 million to $10 million. In the same amendment, the long-term loan was recast as a $10 million instrument with 48 monthly payments of $85 thousand each and a remaining balance due on July 9, 2029, while the 2025 annual investment cap was raised from $12 million to $21 million. That is a crucial signal. The pressure point in 2025 was funding room for working capital and investment, not “high leverage” in the simple sense.
The structure of the agreement matters too. Total financing capacity with the bank stands at up to $64.425 million, centered around a facility of up to $50 million for Tefron Canada and Tefron USA, based on collateral tested monthly. In addition, the agreement leaves the financing at the bank’s discretion and includes customary immediate-repayment triggers, including breaches of other credit agreements above $2 million. So even without a covenant breach, bank dependence remains part of the story.
What Has To Change For The 2026 Test To Ease
2026 will not be judged only through the revenue line. It will be judged through whether the funding structure starts to rotate back from bank dependence toward a more natural operating cash cycle.
- Brands need to recover enough volume to rebuild EBITDA and open more room under debt-service coverage.
- Inventory days need to come down, or at least stop rising, so that expanded recognition of in-transit inventory does not remain part of the financing oxygen.
- Customer days need to stabilize without heavier dependence on accelerated-payment programs, or the receivables improvement will remain only partial.
- Supplier funding does not need to return all the way to 2024 levels, but the business does need to show it can move through 2026 without pushing even more of working-capital financing onto the bank.
Conclusion
The main article argued that the balance sheet funded the transition year. This follow-up shows the mechanics: receivables looked better, but terms actually lengthened; inventory did not come down; suppliers funded less; and the bank filled the gap. That is why the key covenant is not debt to EBITDA, which remains very comfortable, but debt-service coverage at 1.32, which sits much closer to the floor.
The fair counter-thesis is that there is no immediate squeeze. Tefron still has unused availability, leverage is low, and the bank already showed willingness in 2025 to adapt the agreement to operating reality. That is a real point. Precisely because of that, though, the 2026 test is not whether the company can secure more availability. It is whether it needs less of it.
The bottom line is simple: in 2026, Tefron does not need to prove that it can roll credit. It needs to prove that the working-capital build and investment burden of 2025 are starting to come back through cash flow, so the bank returns to being a support layer rather than the center of the story.